Drugs / NTX-2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07520292 | Mar 2026 → Mar 2027 expected | alcohol-related disorders | Newleos Therapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-29 | Newleos Therapeutics, Inc. | Newleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use Disorder newleos.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07520292 ↗ |
| Action | Activate | “a novel TAAR1 receptor partial agonist (NTX-2001)” NCT07520292 ↗ |
| Target | TAAR1 | “a novel TAAR1 receptor partial agonist (NTX-2001)” NCT07520292 ↗ |